Andrea Necchi: Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with mCRPC
Andrea Necchi, Associate Editor of the Journal of Clinical Oncology, shared his recent article on X:
“PARP inhibitors Cv safety in full.”
Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis.
Authors: Brigida Anna Maiorano, et al.
The article provides a systematic review and meta-analysis on the safety of PARP inhibitors (PARPi) in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on cardiovascular and thromboembolic adverse events. The study analyzes data from 11 clinical trials, revealing that while hypertension is the most common adverse event associated with PARPi treatment, the risk of major adverse cardiovascular events (MACEs) and thromboembolic events is notably higher compared to other treatments.
Key findings include:
- Hypertension was reported in 17.2% of patients, with 9.3% experiencing high-grade hypertension.
- The use of PARPi was associated with a significantly increased risk of high-grade MACEs (risk ratio [RR] 2.03) and thromboembolic events (RR 2.15), particularly venous thromboembolism (RR 2.13) and pulmonary embolism (RR 3.60).
- Despite these findings, the overall incidence of serious cardiovascular complications remains low, indicating that while risks exist, they are relatively rare.
The authors emphasize the need for clinicians to be vigilant regarding these potential risks, especially in patients who may have pre-existing cardiovascular conditions. The study highlights the importance of monitoring and managing these adverse effects to improve patient outcomes while using PARPi therapies.
In summary, while PARP inhibitors are effective for treating mCRPC, their association with increased cardiovascular toxicity necessitates careful consideration and management in clinical practice.
More posts featuring Andrea Necchi.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023